Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04227288 · ClinicalTrials.gov registry record · Phase 4
A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT04227288 is a Phase 4 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 6 participants.
The verdict
NCT04227288, a Phase 4 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
The aim of the study is to evaluate the efficacy and safety of Enstilar Foam (calcipotriene and betamethasone dipropionate) for the treatment of nail psoriasis.
Interventions
- DRUG Enstilar Foam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04227288
The ClinicalTrials.gov registry entry for NCT04227288 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enstilar Foam is the first listed.
NCT04227288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04227288 about?
NCT04227288 is a clinical study titled "A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis". The aim of the study is to evaluate the efficacy and safety of Enstilar Foam (calcipotriene and betamethasone dipropionate) for the treatment of nail psoriasis.
What is the current status of trial NCT04227288?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2021-11-01. Estimated completion is 2023-10-31.
What interventions are being tested in trial NCT04227288?
The interventions under investigation include: Enstilar Foam (DRUG).
Who is sponsoring clinical trial NCT04227288?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.